// App-Quantinova.ai

552 : Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial

Researchers

Presenter

  • H Duygu Saatcioglu

Principal Investigators

  • Juan Valle

  • Teresa Macarulla

  • Milind Javle

  • Do-Youn Oh

  • Lipika Goyal

  • Jake Conway

  • Janani Iyer

  • Fedaa Najdawi

  • Chintan Shah

  • Camelia Gliser

  • Susan Pandya

  • Scott Daigle

  • Ghassan Abou-Alfa

  • Robin Kelley

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • University of Manchester and Department, Manchester, UK

  • Pathology, MD ANDERSON CANCER CENTER, Houston, Texas, United States

  • Paratek Pharmaceuticals, Boston, MA, United States,

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • PathAI, Boston, MA, United States

  • Seoul National University College of Medicine, Seoul, Korea

  • Hematologia, Hospital Universitario Vall de Hebron, Barcelona, Spain

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • United States

  • Spain

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT02989857

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved